Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 389-399

  Abramson, Vandana G ^a,c   Cooper Lloyd, M ^a   Ballinger, Tarah ^a   Sanders, Melinda E ^a,c   Du, Liping ^b   Lai, Darson ^b   Su, Zengliu ^b   Mayer, Ingrid ^a,c   Levy, Mia ^a,c   Lafrance, Delecia R ^a   Vnencak Jones, Cindy L ^a   Shyr, Yu ^b   Dahlman, Kimberly B ^b   Pao, William ^a,b,c   Arteaga, Carlos L ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Breast cancer; PI3K; PIK3CA mutation; SNaPshot

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC EQUIPMENT; FEASIBILITY STUDY; FEMALE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MUTATION RATE; MUTATIONAL ANALYSIS; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GENE; UNITED STATES; WILD TYPE; BREAST TUMOR; CASE REPORT; CLINICAL TRIAL (TOPIC); DNA MUTATIONAL ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PATIENT PARTICIPATION; PROCEDURES; TIME FACTOR; TUMOR RECURRENCE; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT PARTICIPATION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 84901690673     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2945-3     Document Type: Article

References (37)

1. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26(9):1338-1345 (Pubitemid 46328463)
2. Campbell IG et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678-7681 (Pubitemid 39446895)
3. Li SY et al (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96(1):91-95
4. Kalinsky K et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049-5059
5. Cizkova M et al (2012) PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14(1):R28
6. Miller TW et al (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13(6):224
7. Maruyama N et al (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13(2 Pt 1):408-414 (Pubitemid 46225343)
8. Janku F et al (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777-782
9. Jensen DJ et al (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667-677
10. Isakoff SJ et al (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65(23):10992-11000 (Pubitemid 41713369)
11. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27(41):5486-5496
12. Gonzalez-Angulo AM et al (2013) Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3- kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15
13. Perez-Tenorio G et al (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13(12):3577-3584 (Pubitemid 46955118)
14. Loi S et al (2013) Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105(13):960-967
15. Saal LH et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554-2559 (Pubitemid 40490050)
16. Dumont AG, Dumont SN, Trent JC (2012) The favorable impact of PIK3CA mutations on survival: An analysis of 2587 patients with breast cancer. Chin J Cancer 31(7):327-334
17. Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452-4461
18. Campbell RA et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276(13):9817-9824
19. Berns K et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402 (Pubitemid 47539306)
20. Eichhorn PJ et al (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68(22):9221-9230
21. Cizkova M et al (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108(9):1807-1809
22. Jensen JD et al (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23(8):2034-2042
23. Baselga, J., et al.,: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). In: Thirty-fifth annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, 4-8 Dec 2012; Cancer. Res. 72(24 Supplement), S5-1 (2012)
24. Baselga J, M.I., Nuciforo PG et al. (2013) PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06). Presented at European Cancer Congress 2013; Sep 27-Oct 1,2013; Amsterdam. Abstract 1859, 2013
25. Janku F et al (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276-284
26. Bendell JC et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282-290
27. Hurst CD et al (2009) A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2:66
28. Su Z et al (2011) A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 13(1):74-84
29. Lovly CM et al (2012) Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 7(4):e35309
30. Hammond ME et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48-e72
31. Wolff AC et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18-43 (Pubitemid 46174133)
32. Zhao L, Vogt PK (2008) Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 105(7):2652-2657 (Pubitemid 351520568)
33. Board RE et al (2008) Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54(4):757-760 (Pubitemid 351573719)
34. Lurkin I et al (2010) Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 5(1):e8802
35. Ramirez-Ardila DE et al (2013) Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat 139(1):39-49
36. Knight WA et al (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669-4671
37. Kinne DW et al (1981) Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47(10):2364-2367 (Pubitemid 11127624)